Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Marker for predicting sensitivity of rectal cancer patient to bevacizumab

A bevacizumab and marker technology, applied in the field of biomedicine, can solve the problem that the sensitivity of bevacizumab is difficult to predict

Inactive Publication Date: 2022-01-14
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the exact effect of bevacizumab on rectal tumors has not been fully elucidated, and the sensitivity of patients to bevacizumab is also difficult to predict

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Marker for predicting sensitivity of rectal cancer patient to bevacizumab
  • Marker for predicting sensitivity of rectal cancer patient to bevacizumab
  • Marker for predicting sensitivity of rectal cancer patient to bevacizumab

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] Example 1, screening predictive markers

[0067] 1. Data download and experimental objects

[0068] Download the gene expression data of GSE60331 from the GEO database, the specific link is https: / / www.ebi.ac.uk / arrayexpress / experiments / E-GEOD-60331 / ? query=GSE60331+.

[0069] In the study of the above database, 59 patients had retained tumor tissue before receiving bevacizumab treatment. When receiving total mesorectal excision (TME) surgery in the later stage, according to the treatment situation of the patients, according to the Dworak / Five-level classification divides patients into two groups: complete remission group (complete remission, CR), also known as responders, is marked as R in the database, and treatment failure group (non-responders, NR), also known as non-responders, is in the database Marked as NR.

[0070] Finally, 21 samples of responders and 26 samples of non-responders were collected; in addition, three samples of NJ 04 / 003T1, RVS 09 / 002M, an...

Embodiment 2

[0075] Example 2, verifying the predictive effect of markers and marker combinations

[0076] The R language pROC package was used to draw the receiver operating curve (ROC), calculate the AUC value, sensitivity and specificity, and judge the predictive performance of the markers. The ROC curves of NKG7, NOX1, CIITA, NKG7+NOX1, NKG7+CIITA, NOX1+CIITA are as follows Figure 2-7 , the AUC values ​​are shown in Table 2.

[0077] Table 2. AUC values ​​of markers or marker combinations

[0078] Markers / Combinations AUC NKG7 0.710145 NOX1 0.79066 CIITA 0.811594 CIITA+NKG7 0.806763 CIITA+NOX1 0.906602 NKG7+NOX1 0.837359

[0079] The above results indicate that the markers provided by the present invention can predict the sensitivity of rectal cancer patients to bevacizumab, and have high clinical application value.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biomedicine, and particularly relates to a marker for predicting the sensitivity of a rectal cancer patient to bevacizumab. Specifically, the invention provides application of a reagent for detecting the expression quantity of one or more of NKG7, NOX1 and CIITA in preparation of a product for predicting the sensitivity of a subject to the bevacizumab. Preferably, the subject is the rectal cancer patient.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a marker for predicting the sensitivity of rectal cancer patients to bevacizumab. Background technique [0002] Rectal cancer refers to malignant tumors that occur above the dentate line of the rectum to the junction of the rectum and the sigmoid colon. More than 80% of rectal cancers in China occur near the anus, and most of them can be found by digital rectal examination. The etiology of rectal cancer is still unclear. Most rectal cancers evolve from adenomatous polyps and go through various stages of hyperplasia, adenoma, and carcinogenesis and corresponding chromosomal changes. Carcinogenesis involves the participation of multiple genes. Although its etiology is not clear, its associated risk factors are gradually being recognized. [0003] The treatment of rectal cancer should adopt the principle of individualized comprehensive treatment. The doctor will apply a vari...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886G01N33/574G01N33/68G01N33/573
CPCC12Q1/6886G01N33/57419G01N33/57484G01N33/68G01N33/573C12Q2600/158C12Q2600/106G01N2333/47G01N2333/90209G01N2333/912G01N2333/91051
Inventor 杨承刚王丹李雨晨
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com